Finance

Lists
TMCI:NASDAQ
Treace Medical Concepts, Inc
၃.၈၆ US$
-၀.၇၇%
(-၀.၀၃၀) 1D
အောက် ၈, GMT-၄ ၁၄:၂၄:၁၃  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TMCI...
Open
၃.၈၇ US$
High
၃.၈၈ US$
Low
၃.၇၈ US$
Mkt. cap
၂၅.၁၀ ကုဋေ
Avg. vol.
၂.၃၅ သိန်း
Volume
၉.၇၅ သောင်း
52-wk high
၇.၀၈ US$
52-wk low
၁.၁၇ US$
EPS
-၀.၉၃ US$
Beta
၁.၄၈
Shares outstanding
၆.၅၀ ကုဋေ
No. of employees
၄၅၀
Open
၃.၈၇ US$
High
၃.၈၈ US$
Low
၃.၇၈ US$
Mkt. cap
၂၅.၁၀ ကုဋေ
Avg. vol.
၂.၃၅ သိန်း
Volume
၉.၇၅ သောင်း
52-wk high
၇.၀၈ US$
52-wk low
၁.၁၇ US$
EPS
-၀.၉၃ US$
Beta
၁.၄၈
Shares outstanding
၆.၅၀ ကုဋေ
No. of employees
၄၅၀
News stories
From web sources and news partners
Benzinga
Benzinga
·
ပြီးခဲ့သည့် ၁ ရက်
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Profile
Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions. In March 2021, Treace announced its intent to launch an initial public offering. Trading on the Nasdaq under the ticker symbol “TMCI”, Treace opened its IPO in April 2021. Wikipedia
About Treace Medical Concepts, Inc
CEO-
Employees၄၅၀
Founded၂၀၁၄
Headquarters-
Sector-
Websitetreace.com
Analyst ratings
Based on 3 analysts giving stock ratings to TMCI in the past 3 months
Buy
Buy
1
Hold
2
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for TMCI in the last 3 months.
Highest
Current ၃.၈၆ US$
၇.၀၀ US$ (+၈၁.၃၅%)
Average
၅.၅၀ US$ (+၄၂.၄၉%)
Lowest
၄.၅၀ US$ (+၁၆.၅၈%)
Analyst
Recommendation
Action
Price target
Projected
Date
Rick Wise
Stifel Nicolaus
Hold
Maintained
၄.၅၀ US$
+၁၆.၆%
08/11/2026
Ben Haynor
Lake Street
Buy
Reiterated
၇.၀၀ US$
+၈၁.၃%
08/10/2026
Richard Newitter
Truist Financial
Hold
Reiterated
၅.၀၀ US$
+၂၉.၅%
08/10/2026
Danielle Antalffy
UBS
Hold
Maintained
၂.၂၅ US$
-၄၁.၇%
03/02/2026
Last report
၂၀၂၆ ဩ ၇
Fiscal period
Q2 2026
-၀.၂၀ US$ / -၀.၃၀ US$
+၃၃.၃၀%beat
Revenue / Est. (USD)
၄.၅၄ ကုဋေ / ၄.၃၉ ကုဋေ
+၃.၃၀%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
၅.၀၂ ကုဋေ
၆.၂၅ ကုဋေ
၄.၇၂ ကုဋေ
၄.၅၄ ကုဋေ
Cost of goods sold
၁.၀၅ ကုဋေ
၁.၂၁ ကုဋေ
၉.၇၉ သန်း
၉.၇၇ သန်း
Cost of revenue
၁.၀၅ ကုဋေ
၁.၂၁ ကုဋေ
၉.၇၉ သန်း
၉.၇၇ သန်း
Research and development expenses
၄.၆၈ သန်း
၄.၅၄ သန်း
၄.၆၂ သန်း
၄.၃၈ သန်း
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၄.၉၇ ကုဋေ
၅.၁၈ ကုဋေ
၅.၀၀ ကုဋေ
၄.၆၂ ကုဋေ
Operating expense
၅.၄၄ ကုဋေ
၅.၆၃ ကုဋေ
၅.၄၆ ကုဋေ
၅.၀၆ ကုဋေ
Total operating expenses
၆.၄၉ ကုဋေ
၆.၈၄ ကုဋေ
၆.၄၄ ကုဋေ
၆.၀၃ ကုဋေ
Operating income
-၁.၄၇ ကုဋေ
-၅.၉၂ သန်း
-၁.၇၂ ကုဋေ
-၁.၅၀ ကုဋေ
Other non operating income
၉.၂၀ သောင်း
၈.၈၀ သောင်း
၂.၇၅ သိန်း
၂.၀၂ သိန်း
EBT including unusual items
-၁.၆၃ ကုဋေ
-၉.၃၉ သန်း
-၁.၈၀ ကုဋေ
-၁.၅၉ ကုဋေ
EBT excluding unusual items
-၁.၅၃ ကုဋေ
-၆.၆၆ သန်း
-၁.၈၀ ကုဋေ
-၁.၅၉ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၁.၆၃ ကုဋေ
-၉.၃၉ သန်း
-၁.၈၀ ကုဋေ
-၁.၅၉ ကုဋေ
Net profit margin
-၃၂.၄၄%
-၁၅.၀၃%
-၃၈.၀၅%
-၃၄.၉၈%
Earnings per share
-၀.၂၂
-၀.၀၈
-၀.၁၂
-၀.၂၀
Interest and investment income
၆.၃၄ သိန်း
၅.၂၇ သိန်း
၅.၀၁ သိန်း
၄.၄၅ သိန်း
Interest expense
-၁.၃၄ သန်း
-၁.၃၅ သန်း
-၁.၅၇ သန်း
-၁.၅၆ သန်း
Net interest expenses
-၇.၀၄ သိန်း
-၈.၂၃ သိန်း
-၁.၀၇ သန်း
-၁.၁၂ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၁.၁၉ ကုဋေ
-၄.၁၁ သန်း
-၁.၆၃ ကုဋေ
-၁.၃၁ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ